The effectiveness of basic therapy in children with primary ciliary dyskinesia

Objective. To evaluate the effectiveness of mucolytic therapy and its impact on the quality of life of children with primary ciliary dyskinesia (PCD). Materials and methods. Analysis of discharge epicrisis of 60 children with PCD who were twice in the department of Pulmonology at the Veltischev Institute from 2023 to 2024. Results. In children with regular therapy, there was a decrease in inflammatory markers in the blood: leukocytes from 8.1±1.28 to 6.8±1.0 thousand/ml, neutrophils from 4.3±1.1 to 3.3±0.56 thousand/ml (p<0.05). Children who had not previously received basic therapy, after initiation of daily mucolytic treatment, showed a significant increase in all indicators of external respiratory function (p<0.05). Also, in these children, the residual lung volume decreased from 196.0±47.8% to 167.0±37.8% (р<0.05). Conversely, in children with irregular therapy, residual lung volume increased from 148.0±28.3% to 172.0±37.0% (р < 0.05). In children with regular therapy, the average quality of life was 73.20±6.66%, compared with 63.20±8.08% in children without basic treatment (p 0.05). Also, in these children, the indicators of the physical and psychological components of health were higher by 10% compared with children whose mucolytic therapy was insufficient: 64.0±8.73% and 74.0±7.1%, 62.0±8.32 and 72.0±7.03%, respectively (p<0.05). Conclusion. Daily mucolytic therapy is vital to improve the condition and quality of life of children with PCD.